The Procoagulant State of the VX-2 Tumor in Rabbit Lung In Vivo

Summary

During their growth, many malignant solid tumors elicit a hemostatic response in the host. In this report, the fluxes of various rabbit plasma hemostatic proteins into pulmonary VX-2 tumors have been measured in vivo. VX-2 cells were contained within a small rabbit plasma clot which was injected intravenously into rabbits. At 28 d, each rabbit was injected intravenously with two radiolabeled (¹³¹I, ¹²⁵I) proteins selected from fibrinogen, prothrombin, antithrombin-α, heparin cofactor II, or plasminogen-I or -II. After allowing the labeled proteins to circulate for 10-200 min, each rabbit was perfused with Krebs-Henseleit solution and the lungs excised. Solid tumors were isolated, weighed and measured for radioactivity content. A mean of 14 tumors/pair of lungs with a mean tumor weight of 0.3 g was obtained. Radioactivity per g of tumor was related to radioactivity/ml of blood at exsanguination for each protein at each time interval. Maximum flux rates were calculated (as pmol/g of tumor/min): Fibrinogen, 65.0; prothrombin, 53.0; antithrombin-α, 24.1; HCII, 17.2; plasminogen-II, 5.0; and plasminogen-I, 3.2. Using immunocytochemical staining, fibrin(ogen) was distributed heterogeneously within the VX-2 tumor, appearing largely in the perinodular region and in the necrotic core. From the net fluxes of these proteins, the profile of chronic hemostasis associated with the VX-2 tumor was shown to differ markedly from the hemostatic response that occurs after an acute vascular injury.

Keywords

Tumor - procoagulant state - hemostasis factors - fibrinogen

• References

• 1 Edwards RL, Rickles FR, Moritz TE, Henderson WG, Zacharski LR, Forman WB, Cornell CJ, Jackson Forcier R, O’Donnell JF, Headley E, Kim S-H, O’Dell R, Tornyos K, Kwaan HC. Abnormalities of blood coagulation tests in patients with cancer. Am J Clin Pathol 1987; 147: 251-3.
• 2 Trousseau A. Phlegmasia alba dolens. Clinique Medicale de l’Hotel-Dieu de Paris 1865; 3: 654-712.
• 3 O’Meara RAQ. Coagulative properties of cancers. Irish J Med Sci 1958; 394: 474-9.
• 4 Kakkar AK, DeRuvo N, Chingwanswatanakul V, Tebbutt S, Williamson RCN. Extrinsic pathway activation in cancer with high factor VIIa and tissue factor. Lancet 1995; 346: 1004-5.
• 5 Gordon SG. Cancer cell procoagulants and their implications. Hematology/Oncology Clinics of North America 1992; 6: 1359-74.
• 6 Zacharski LR, Constantini V, Wojtukiewicz MZ, Memoli VA, Kudryk BJ. Anticoagulants as cancer therapy. Semin Oncol 1990; 17: 217-27.
• 7 Wojtukiewicz MZ, Zacharski LR, Memoli VA, Kisiel W, Kudryk BJ, Rousseau SM, Stump DC. Abnormal regulation of coagulation/fibrinolysis in small cell carcinoma of the lung. Cancer 1990; 65: 481-5.
• 8 Wojtukiewicz MZ, Zacharski LR, Memoli VA, Kisiel W, Kudryk BJ, Moritz TE, Rousseau SM, Stump DC. Fibrin formation on vessel walls in hyperplastic and malignant prostate tissue. Cancer 1991; 67: 1377-83.
• 9 Contrino J, Hair G, Kreutzer DL, Rickles FR. In situ detection of tissue factor in vascular endothelial cells: Correlation with the malignant phenotype of human breast disease. Nature Med 1996; 2: 209-15.
• 10 Poggi A, Polentarutti N, Donati MB, De Gaetano G, Garattini S. Blood coagulation changes in mice bearing Lewis lung carcinoma. Cancer Res 1977; 37: 272-7.
• 11 Brown LF, Van De Water L, Harvey VS, Dvorak H. Fibrinogen influx and accumulation of cross-linked fibrin in healing wounds and in tumor stroma. Am J Pathol 1988; 130: 455-65.
• 12 Hatton MWC, Ross B, Southward SMD, DeReske M, Hoogendoorn H, Blajchman MA, Richardson M. Uptake of heparin cofactor II and antithrombin into the aorta wall following a deendothelializing injury in vivo: Comparison with the behaviors of prothrombin and fibrinogen. J Lab Clin Med 1999; 133: 81-7.
• 13 Hatton MWC, Moar SL, Richardson M. Deendothelialization in vivo initiates a thrombogenic reaction at the rabbit aorta surface: Correlation of uptake of fibrinogen and antithrombin-III with thrombin generation by the exposed subendothelium. Am J Pathol 1989; 135: 499-508.
• 14 Hatton MWC, Southward SMR, Serebrin SD, Kulczycky M, Blajchman MA. Catabolism of rabbit prothrombin in rabbits: Uptake of prothrombin by the aorta wall before and after a de-endothelializing injury in vivo. J Lab Clin Med 1995; 126: 521-9.
• 15 Hatton MWC, Southward SMR, Ross-Ouellet B. Catabolism of plasminogen glycoforms I and II in rabbits: Relationship to plasminogen synthesis by the rabbit liver in vivo. Metabolism 1994; 43: 1430-7.
• 16 Witmer MR, Hatton MWC. Antithrombin III-β associates more readily than antithrombin III-α with the uninjured and deendothelialized rabbit aortic wall in vitro and in vivo. Arterioscler Thromb 1991; 11: 530-9.
• 17 Hatton MWC, Hoogendoorn H, Southward SMR, Ross B, Blajchman MA. Comparative metabolism of rabbit heparin cofactor II and rabbit antithrombin in rabbits. Am J Physiol 1997; 272 (Endocrin Metab 35) E824-31.
• 18 Aster RH, Jandl JH. Platelet sequestration in man. I. Methods. J Clin Invest 1964; 43: 843-54.
• 19 Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680-5.
• 20 Reisfeld RA, Lewis UJ, Williams DE. Disk electrophoresis of basic proteins and peptides on polyacrylamide gels. Nature 1962; 195: 281-3.
• 21 Fraker PJ, Speck JC. Protein and cell membrane iodinations with a sparingly soluble chloramide, 1,3,4,6-tetrachloro-3a,6a-diphenylglycoluril. Biochem Biophys Res Commun 1978; 80: 849-57.
• 22 Bolton AE, Hunter WM. The labelling of proteins to high specific radioactivities by conjugation to a ¹²⁵I-containing acylating agent. Biochem J 1973; 133: 529-39.
• 23 Olfert ED, Cross BM, McWilliam AA. eds. Guide to the Care and Use of Experimental Animals. 1. 2nd Edition. Canadian Council On Animal Care. 1993
• 24 Stetson PL, Maybaum J, Wagner JG, Averill DR, Wollner IS, Knol JA, Johnson NJ, Yang Z, Preiskorn D, Smith P, Knutsen CA, Ensminger WD. Tissue-specific pharmacodynamics of 5-bromo-2’-deoxyuridine incorporation into DNA in VX-2 tumor-bearing rabbits. Cancer Res 1988; 48: 6900-5.
• 25 Hatton MWC, Berry LR, Regoeczi E. Inhibition of thrombin by antithrombin III in the presence of certain glycosaminoglycans found in the mammalian aorta. Thromb Res 1978; 13: 655-70.
• 26 Witmer MR, Hadcock SJ, Peltier SL, Winocour PD, Richardson M, Hatton MWC. Altered levels of antithrombin III and fibrinogen in the aortic wall of the alloxan-induced diabetic rabbit: Evidence of a prothrombotic state. J Lab Clin Med 1992; 119: 221-30.
• 27 Hatton MWC, Southward SMR, Blajchman MA, Ross B, Winocour PD, Richardson M. Comparative catabolism of prothrombin and antithrombin in normal and alloxan-diabetic rabbits. Metabolism 1997; 46: 1406-11.
• 28 Hatton MWC, Day S, Ross B, Southward SMR, DeReske M, Richardson M. Plasminogen-II accumulates five times faster than plasminogen-I at the site of a balloon de-endothelializing injury in vivo to the rabbit aorta: Comparison with other hemostatic proteins. J Lab Clin Med 1999; 134: 260-6.
• 29 Richardson M, DeReske M, Hoogendoorn H, Southward SMR, Ross B, Hatton MWC. Fibrin deposition within the wall of the balloon-deendothelialized rabbit aorta continues throughout reendothelialization. Submitted for publication..
• 30 Dvorak H. Tumors: Wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 1986; 315: 1650-9.
• 31 Shoji M, Hancock WW, Abe K, Micko C, Casper KA, Baine RM, Wilcox JN, Danave I, Dillehay DL, Matthews E, Contrino J, Morrissey JH, Gordon S, Edgington TS, Kudryk B, Kreutzer DL, Rickles FR. Activation of coagulation and angiogenesis. Immunohistochemical localization in situ of clotting proteins and vascular endothelial growth factor in human cancer. Am J Pathol 1998; 152: 399-411.
• 32 Cliffton EE, Grossi CE. Effect of human plasmin on the toxic effects and growth of blood-borne metastasis of the Brown-Pearce carcinoma and the V2 carcinoma of rabbit. Cancer 1956; 9: 1147-52.
• 33 Wood S, Hilgard PH. Arvin-induced hypofibrinogenemia and metastasis formation from blood-borne cancer cells. Hopkins Med J 1973; 133: 207-13.
• 34 Ashford A, Ross J, Southgate P. Pharmacology and toxicology of a defibrinating substance from Malayan pit viper venom. Lancet 1968; i: 486-9.